SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : corgenix

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: RikRichter12/17/2007 1:20:30 PM
   of 191
 
Corgenix and NIH to Develop Predictive Model for Liver Fibrosis
Dec. 17, 2007, 11:16 AM EST
Genetic Engineering and Biotechnology News
GEN News Highlights

Corgenix Medical entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK).

The two-year study will use Corgenix’ Hyaluronic Acid (HA) test kit alone, and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in nonalcoholic steatohepatitis (NASH) patients. NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-NIDDK study is focused on developing a noninvasive method of diagnosis.

“This is a definitive study that will apply our HA product to an important and clearly underdiagnosed condition that affects a significant percentage of the U.S. population,” says Corgenix president and CEO Douglass Simpson. “With the rate of obesity in the U.S. continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, noninvasive methods for assessment.”

The Corgenix Hyaluronic Acid test kit has not been cleared by the FDA for in vitro diagnostic use in the U.S., but it is CE-marked for sale in the European Union.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext